The Bioinformatics Analysis of miRNAs Signatures Differentially Expressed in HER2(+) Versus HER2(-) Breast Cancers

被引:3
|
作者
Nie, Weiwei [1 ]
Jin, Lei [2 ]
Wang, Yanru [1 ]
Wang, Zexing [3 ]
Guan, Xiaoxiang [1 ,3 ]
机构
[1] So Med Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[2] Nanjing Univ, Jinling Hosp, Sch Med, Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China
[3] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
bioinformatics; breast cancer; HER2; miRNAs; MICRORNAS;
D O I
10.1089/cbr.2012.1311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To identify the signatures of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers that accurately predict the HER2 status of breast cancer, and to provide further insight into breast cancer therapy. Methods: By the methods of literature search, aberrant expressed miRNAs were collected. By target prediction algorithm of TargetScan and PicTar and the data enrichment analysis, target gene sets of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers were built. Then, using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database, the function modules of Gene Ontology categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) and BIOCARTA pathway, biological functions and signaling pathways that are probably regulated by miRNAs, were analyzed. Results: We got five sets of miRNAs expressed in different HER2 status of breast cancers finally. The five sets of data contain 22; 32; 3; 38; and 62 miRNAs, respectively. After miRNAs target prediction and data enrichment, 5,734; 22,409; 1,142; 22,293; and 43,460 target genes of five miRNA sets were collected. Gene ontology analysis found these genes may be involved in transcription, protein transport, angiogenesis, and apoptosis. Moreover, certain KEGG and BIOCARTA signaling pathways related toHER2 status were found. Conclusion: Using TargetScan and PicTar for data enrichment, and DAVID database, Gene Ontology categories, KEGG and BIOCARTA pathway for analysis of miRNAs different expression, we conducted a new method for biological interpretation of miRNA profiling data in HER2(+) versus HER2(-) breast cancers. It may improve understanding the regulatory roles of miRNAs in different molecular subtypes of breast cancers. Therefore, it is beneficial to improve the accuracy of experimental efforts to breast cancer and potential therapeutic targets.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [31] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [32] Her2/neu status in bone metastases of breast cancers
    Lörincz, T
    Tóth, J
    Szendröi, M
    Tímár, J
    PROCEEDINGS OF THE 2ND CONGRESS OF THE WORLD SOCIETY FOR BREAST HEALTH, 2003, : 35 - 38
  • [33] Adjuvant chemotherapy of breast cancers with overexpression or HER2 amplification
    Petit, Thierry
    ONCOLOGIE, 2008, 10 : S64 - S67
  • [34] Comparative Analysis of Four Immunohistochemical Assays for HER2 Expression in Breast Carcinoma - Correlation with HER2 Gene Amplification and Perspectives for HER2 Low Expression
    Nielsen, Soren
    Wang, Diana
    Calero, Valeria Montalvo
    LaMar, Jared
    Saxena, Ashish
    Decamillis, Rina
    Stensballe, Mia
    LABORATORY INVESTIGATION, 2023, 103 (03) : S192 - S192
  • [35] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    LABORATORY INVESTIGATION, 2019, 99
  • [36] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
  • [37] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Yao-Shan Fan
    Carmen E. Casas
    Jinghong Peng
    Melanie Watkins
    Lynn Fan
    Jennifer Chapman
    Offiong Francis Ikpatt
    Carmen Gomez
    Wei Zhao
    Isildinha M. Reis
    Breast Cancer Research and Treatment, 2016, 155 : 457 - 462
  • [38] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [39] Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation
    Wang, Y-C
    Hennessy, B.
    Ward, McAnnich R.
    Rimawi, M.
    Huang, C.
    Mills, G. B.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2009, 69 (24) : 526S - 526S
  • [40] Characteristics of HER2 FISH-Equivocal Breast Cancers and the Impacts on HER2 Status of 2018 ASCO/CAP Guideline
    Kong, Hui
    Bai, Qianming
    Lu, Hongfen
    Zhou, Xiaoyan
    Yang, Wentao
    MODERN PATHOLOGY, 2019, 32